Tolerability of a recombinant DNA hepatitis B vaccine - Results of post-marketing surveillance

Journal of Communicable Diseases

Volumn 31, Issue 1, 1999, Pages 53-55

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE; RECOMBINANT VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; HUMAN; INFANT; NEWBORN; POSTMARKETING SURVEILLANCE; PRESCHOOL CHILD;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; HEPATITIS B VACCINES; HUMANS; INFANT; INFANT, NEWBORN; PRODUCT SURVEILLANCE, POSTMARKETING; VACCINES, SYNTHETIC;

EID: 0033085666     PISSN: 00195138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Wainwright, R.B., et al. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. JAMA 1989, 261(16);2362-6.
2. Eduardo Penton., Varena Muzio, and Martha Gonzalez-Griego. The hepatitis B virus (HBV) infection and its prevention by a recombinant-DNA surface antigen (rec-HBsAg) Vaccine. Biotecnologia aplicada 1994, 11(1); 1-11.
3. Galban Garcia, E. et al. Field trial of the Cuban recombinant vaccine against hepatitis B (Heberbiovac HB). Study in newborn infants born to AgsHB +mothers. Revista Cubana de Medicinia Tropical 1992, 44(2); 149-57.
4. Diaz Gonzalez, M. et al. Adverse reactions and immune response to Heberbiovac-HB vaccine administered to infants simultaneously with DPT and VA-MENGOC-BC]-Revista Cubana de Medicina Tropical 1997, 49(3); 196-203.
5. Grotto, I, et al (1998). Major adverse reactions to yeast derived hepatitis B vaccines - a review. Vaccine 1998, 16(4); 329-334.
6. Bonfils, P., et al (1996). Fluctuant perception hearing loss after hepatitis B Vaccine. Annales D Oto-Laryngologie et de chiyrgie Cervico-Faciale 1996, 113(6);359-61.